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ABSTRACT
Currently, the number of novel psychoactive substances (NPS) has significantly increased. Recent reports 
on the abuse of synthetic cathinones focus on serious physical and psychological risks resulting from their 
consumption, thereby emphasising that a growing use of these drugs might constitute an important public 
health. Case report: A young man presented to the emergency department with acute designer drug intox-
ication complicated with severe respiratory failure. Why should an emergency physician be aware of this? 
We observe a growing use of NPS among young people. Further studies describing clinical manifestations 
of intoxication and toxicity of synthetic cathinones and treatment guidelines are still needed.
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INTRODUCTION
“Designer drugs”, “legal highs” refer to a wide 
range of products containing novel psychoactive 
substances (NPS). Such substances have become of 
increasing concern around the world. Based on the 
spectrum of exerted psychoactive effects, NPS can 
be classified into four basic categories, which are 
as follows: synthetic cannabinoids (SCs), stimulants, 
opioid-like compounds and hallucinogenic/dissoci-
ative substances (psycholeptics). However, a com-
bination of the adverse effects may be observed 
due to their different chemical structure. The most 
common groups are SCs and psychostimulants [1]. 
These substances are usually sold labelled as “not for 
human consumption” and to avoid criminal liability, 
under trivial names, such as “bath salts”, “plant 
fertilisers” or “incense”. The European Monitoring 
Centre for Drugs and Drug Addiction (EMCDDA) 
operates the European Union’s “Early Warning Sys-
tem” for NPS, monitoring over 350 NPS. According 
to the most recent report, 81 NPS were notified 
for the first time in 2013 [2]. Their use often goes 
undetected, because routine drug screening may 
not detect them. Moreover, these substances can 
be associated with significant toxicity, often due to 
unpredictable concentrations [1–2]. The increase in 
the number of NPS recorded on the drug market 
between 2010 and 2015 in Poland caused a decisive 
action implemented by Polish government adminis-
tration resulting in the closure of shops selling “legal 
highs”. Unfortunately, the effects of such actions 
were short-lived, since selling NPS mainly through 
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the Internet is gradually increasing. According to 
the reports of the Chief Sanitary Inspectorate, the 
average intoxication rate in 2015 in Poland was 
about 18.92 cases/100 000 inhabitants, what gives 
about 300 cases monthly [3]. In 2015 the Polish 
Ministry of Health confirmed 75 deaths due to NPS 
intoxications [4]. 
The most frequently identified NPS in Po-
land in 2014 were the following: (1-pentylin-
dol-3-yl)-(2,2,3,3-tetramethylcyclopropyl) meth-
anone (UR-144), 3-methylomethcathinone (3-MMC) 
and pentedrone [5]. One of the most common 
designer drugs is the so-called Talisman, sold on 
Polish and German markets. It is easy to purchase 
through online shops and the price ranges between 
€ 7–14 [6–7]. Talisman is a psychostimulant and con-
tains different NPS, i.e. cocaine-MDMA-mixed cathi-
nones, e.g., mephedrone (4-methylmethcathinone), 
methylone (3,4-methylenedioxymethcathinone) and 
ethylone [3]. Regrettably, there is little information 
on the pharmacology and pharmacokinetics of NPS 
and the available data are mainly limited to synthetic 
cathinones and benzylpiperazine (BZP). 
We report a case of acute NPS intoxication after 
the use of a designer drug known as Talisman or 
Talisman Thor Hammer, containing cocaine or MD-
MA-mixed cathinones. The paper discusses a short 
review of clinical, pharmacological and current 
treatment aspects of synthetic cathinones.
CASE REPORT
A 23-year-old man was brought to the emergency 
department (ED) by paramedics with possible de-
signer drug intoxication. The patient’s mother heard 
him scream and the patient had hallucinations. Then 
his mother described a seizure-like activity followed 
by cyanosis, gasping for breath and unresponsive-
ness. The patient’s mother admitted her son had 
a history of heavy and regular drug abuse. In his 
room parents found NPS known as Talisman Thor 
Hammer, which can be delivered to the system orally 
or by insufflation. By the time paramedics arrived, 
the symptoms had become severe. The patient was 
lying prone. On physical examination patient’s level 
of consciousness as assessed by the AVPU scale 
was U (unresponsive) and GCS score was 6. Pupils 
were mid-positioned and poorly reactive. Pre-hos-
pital heart rate was 150 bpm, respiratory rate 
8 breaths/min, sO2 — 81%, blood pressure (BP) 
210/110 mm Hg and glucose level 114 mg/dl. Due 
to airway obstruction and seizures, after intravenous 
administration of weight-based doses of induction 
agents (midazolam and propofol), endotracheal in-
tubation was performed without complications. The 
patient required mechanical ventilation, oxygen and 
i.v. fluids (normal saline). Re-evaluation showed 
heart rate 80 bpm, sO2 — 96%, blood pressure 
160/80 mm Hg and normal sinus rhythm on ECG. 
The patient was brought to the ED and then admit-
ted to the Intensive Care Unit (ICU). When admit-
ted to the ICU, the patient was unconscious (GCS 
score 4). The seizures and spasms persisted and pu-
pils were semi-dilated and unresponsive. In order to 
exclude brain injury, a brain CT scan was performed. 
Blood samples were obtained for toxicological ana-
lysis. Central line catheter and an arterial cannula 
were placed, BP was 100/60, CVP 4 cm H2O. 0.5 mg 
atropine was administered twice due to bradycardia 
(< 50 bpm). The spontaneous diuresis was 100 ml 
per hour, and when diuresis was forced with crys-
talloids, it increased by over 200 ml per hour. The 
patient was sedated with midazolam and, within 
the first 12 hours, additionally with thiopental due 
to persistent spasms, seizures and psychomotor agi-
tation. Then thiopental was discontinued and in the 
next six hours when the patient remained stable, 
midazolam was also discontinued. The patient was 
extubated after the return of consciousness, but 
remained occasionally confused. Laboratory findings 
done within the first 24 hours revealed elevated cre-
atine kinase. Large amounts of fluids were adminis-
tered to maintain forced diuresis. After three days, 
when there was no need for mechanical ventilation, 
the patient was still weak, but conscious and left the 
hospital against medical advice.
DISCUSSION
Epidemiological data and a route of 
administration
According to U.S. Drug Enforcement Administra-
tion, in 2012 methylone was reported to be the 
11th most common hallucinogen within the United 
States [8]. Furthermore, mephedrone was the most 
common synthetic cathinone between 2008 and 
2010 in the majority of European countries. After 
a number of fatal intoxications associated with this 
substance, control measures were taken to min-
imise this phenomenon [9]. Currently the most 
commonly detected compounds in Poland are the 
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following: cathinones 3-MMC, pentedrone and 
MDPBP, and synthetic cannabinoid UR-144. These 
five compounds constitute over 75% of all identi-
fications. Users of these drugs tend to be males, 
either youth or young adults [10]. Cathinones are 
frequently used on weekend nights at night clubs 
or discos. Mephedrone is popular among men who 
have sex with men (MSM), who use the drug solely 
to facilitate sex. An increased spread of HIV and oth-
er sexually transmitted infections is reported in this 
subpopulation [10]. The most common routes of 
NPS administration are insufflation (snorting), oral 
ingestion of capsules or tablets: the substance being 
diluted with water/juice drink or taken as a pow-
der wrapped in a cigarette paper and swallowed 
— this is the so-called bombing or hammer meth-
od used to consume high doses. Rectal insertion, 
intravenous/intramuscular injections and smoking 
were also noted [11–13]. It is reported, that injec-
tions of mephedrone resulted in vein blockages with 
development of skin erosion, localised infections, 
blisters, spots scabs, gangrenous tissue, blood clots 
and large holes at overused injecting sites [14–15]. 
Pharmacokinetics/pharmacology and 
metabolism of synthetic cathinones
Synthetic cathinones exert their action via increasing 
synaptic levels of monoamines, i.e. noradrenaline 
(NA), dopamine (DA), and serotonin (5-HT). It is 
postulated that these drugs interact with the plasma 
membrane monoamine transporter proteins: NAT, 
DAT and SERT, inhibiting reuptake of NA, DA, and 
5-HT. Some drugs can also promote the release of DA 
[16, 17]. The discussed group of NPS may be classi-
fied into four groups based on their relative potency 
to act as SERT, NAT and DAT inhibitors and their ac-
tion as substrate releasers [16, 17] (Tab.1). Focusing 
on the cellular level, mephedrone has been shown to 
increase Fos expression in the cortex, striatum, and 
ventral tegmental area of the rat brain, resembling 
the action of methamphetamine and MDMA in the 
supraoptic nucleus, which is characteristic of MDMA 
[18]. Several studies on the metabolism of cathinone 
derivates in rats and humans indicate that they un-
dergo complex transformation: N-demethylation to 
the primary amine, reduction of the keto group to 
the hydroxyl group, and oxidation of the totyl moie-
ty to the corresponding alcohol and carboxylic acid 
[16–18]. The main enzyme responsible for the in 
vitro phase I metabolism of mephedrone and methy-
lone is cytochrome P 450 2D6 (CYP2D6). Phase I me-
tabolites are eliminated with urine as glucuronide 
conjugates and sulfate conjugates. CYP2D6 plays an 
important clinical role in the metabolism of cathi-
nones. Moreover, this enzyme is involved in the me-
tabolism of numerous drugs and xenobiotics and 
pharmacokinetic interactions between psychostimu-
lants or other compounds are likely to occur. The rate 
of metabolism and toxicity of NPS may depend on 
the genetic polymorphism of CYPP2D6 [18].
Adverse effects/fatal intoxications
The adverse effects associated with the use of syn-
thetic cathinones include a vast array of symptoms, 
which can be divided into groups summarised in 
Table 2 [19, 20]. The highest number of fatal intoxi-
cations is reported for mephedrone. In the majority 
of these cases, the substances were identified post 
mortem. Most of the victims were young males with 
a previous history of drug abuse. The victims usually 
died due to cardiac arrest or respiratory failure, and 
less frequently due to multiorgan failure, disseminat-
ed intravascular coagulation, haemorrhages or fatal 
wounds [13, 15, 19, 20].
Table 1. Synthetic cathinones classified into groups based on inhibition activity
Substance Activity
Cocaine-MDMA-mixed cathinones e.g. mephedrone,  
methylone, ethylone, butylone, naphyrone
Non-selective monoamine uptake inhibitors, five times higher 
affinity for DAT than the affinity for SERT
Mephedrone enhances the release of DA
Methamphetamine-like cathinones e.g. cathinone, 
methcathinone, flephedrone, ethcathinone, 
3-fluoromethcathinone
By analogy to amphetamine and methamphetamine they act 
as preferential catecholamine (DA and NA) uptake inhibitors 
and with an exception of ethcathinone, DA releasers
MDMA-like cathinones e.g. methedrone and 
4-trifluoromethylmethcathinone
Potent NAT and SERT inhibitors with low potency at DAT
Release NA and 5-HT
Pyrovalerone-cathinones e.g. pyrovalerone and MDPV Very potent and selective catecholamine uptake inhibitors,  
do not evoke the release of monoamines
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Management protocol of acute intoxications 
with NPS
There have been no specific treatment guidelines 
for NPS intoxication as yet. Management of patients 
consists in their stabilisation combined with sup-
portive and symptomatic care. Renal, muscular, car-
diovascular, respiratory and hepatic functions should 
be monitored [13–15]. Also in pre-hospital settings 
the procedures of advanced cardiovascular life sup-
port should be maintained if needed. Patients with 
hyperthermia may need serial temperature checks 
during hospitalisation. Agitation and seizures are 
treated with benzodiazepines (lorazepam, mida-
zolam), aggression and psychosis usually require 
the use of antipsychotic drugs. In cases of cardiac 
arrest or respiratory failure, tracheal intubation and 
mechanical ventilation are recommended. It is still 
controversial whether aggressive and violent pa-
tients should be sedated. This issue requires further 
investigation [13–15, 19]. 
WHY SHOULD AN EMERGENCY PHYSICIAN 
BE AWARE OF THIS?
To date the exact prevalence of NPS misuse re-
mains underestimated. There is also an urgent need 
to better understand various compounds of NPS 
(pharmacodynamics, kinetics, toxicity profile, risk 
of dependency), and short- and long-term risks to 
physical and mental health. Treatment for patients 
with acute and prolonged exposure to synthetic 
cathinones is primarily symptomatic. The assessment 
options should include a drug management plan 
coupled with psychotherapy. Developing clinical re-
search into addiction and acute poisonings related 
to NPS should be considered a public health priority.
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